EFFECT OF PROSTATIC INHIBIN PEPTIDE (PIP) ON PROSTATE-CANCER CELL-GROWTH INVITRO AND INVIVO
EFFECT OF PROSTATIC INHIBIN PEPTIDE (PIP) ON PROSTATE-CANCER CELL-GROWTH INVITRO AND INVIVO
复制标题
DOI：
10.1002/pros.2990220305
复制
发表时间：
1993-01-01
期刊：
影响因子：
2.8
通讯作者：
PIENTA, KJ
中科院分区：
文献类型：
--
作者：
GARDE, S;SHETH, A;PIENTA, KJ
前列腺素肽（PIP）是由前列腺以雄激素非依赖性方式分泌的94个氨基酸的蛋白质。以前，已经证明PIP似乎抑制垂体和前列腺的卵泡刺激素（FSH）分泌。在体外，Dunning R3327大鼠前列腺癌细胞系MAT-LyLu（MLL）细胞和人前列腺癌细胞系PC-3响应于外源FSH而被刺激生长，并且这些作用被PIP阻断。在体内，PIP抑制高转移性MLL前列腺癌细胞系的生长。对照组和PIP给药组大鼠的激素水平比较表明，给药组动物的FSH显著抑制。看来，在体内，PIP可以通过抑制FSH来抑制前列腺癌的生长。PIP可能代表一种新的前列腺癌激素治疗。
Prostatic inhibin peptide (PIP), is a 94 amino acid protein which is secreted by the prostate gland in an androgen-independent manner. Previously, it has been demonstrated that PIP appears to inhibit follicle-stimulating-hormone (FSH) secretion by the pituitary and prostate glands. In vitro, the Dunning R3327 rat prostate cancer cell line MAT-LyLu (MLL) cells and the human prostate cancer cell line PC-3, are stimulated to grow in response to exogenous FSH and these effects are blocked by PIP. In vivo, PIP inhibits the growth of the highly metastatic MLL prostate cancer cell line. A comparison of hormone levels in control and PIP-treated rats demonstrates a significant inhibition of FSH in treated animals. It appears that, in vivo, PIP may inhibit prostate cancer growth by inhibiting FSH. PIP may represent a novel hormonal treatment for prostate cancer.